Education
About Us
Working with TipRanks
Follow Us
Neuronetics (STIM)
:STIM
STIM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.52 - $5.92
Previous CloseN/A
Volume92.55K
Average Volume (3M)745.90K
Market Cap
$255.38M
Enterprise Value$355.75M
Total Cash (Recent Filing)$18.66M
Total Debt (Recent Filing)$82.63M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Aug 12, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding65,820,340
10 Day Avg. Volume435,160
30 Day Avg. Volume745,903
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)5.76
Price to Sales (P/S)0.00
P/FCF Ratio-8.98
Enterprise Value/Market Cap1.39
Enterprise Value/Revenue1.21
Enterprise Value/Gross Profit6.64
Enterprise Value/Ebitda-3.38
Forecast
1Y Price Target
$8.00Price Target Upside108.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Neuronetics News
PremiumCompany Announcements
Neuronetics Holds Annual Meeting, Elects Directors
PremiumCompany Announcements
Neuronetics Reports Strong Q1 2025 Growth
PremiumCompany Announcements
Neuronetics Reports Strong Q1 Growth Amid ChallengesBulls Say, Bears Say
Bulls Say
Financial PerformanceSTIM reported a solid Q1 operationally, with revenue of $32.0M, well above consensus estimates.
Growth PotentialManagement updated its FY25 guidance, raising the low-end of its revenue range, indicating confidence in future growth.
Strategic ExpansionGreenbrook was the bright spot of the quarter as the company expands the rollout of Spravato and its buy-and-bill model.
Bears Say
Cash Flow ConcernsThe stock traded off on the higher-than-expected cash burn for Q1.
Margin PressureGross margin decreased to 66.2% from 77.6% due to the inclusion of the lower margin Greenbrook operations.
Segment PerformanceWeakness in the core Neuronetics segment was driven primarily by treatment session revenues, partly offset by system sales.
Ownership Overview
8.68% Insiders
2.77% Mutual Funds
10.84% Other Institutional Investors
73.99% Public Companies and Individual Investors
STIM FAQ
What was Neuronetics’s price range in the past 12 months?
Neuronetics lowest stock price was $0.52 and its highest was $5.92 in the past 12 months.
What is Neuronetics’s market cap?
Neuronetics’s market cap is $255.38M.
When is Neuronetics’s upcoming earnings report date?
Neuronetics’s upcoming earnings report date is Aug 12, 2025 which is in 66 days.
How were Neuronetics’s earnings last quarter?
Neuronetics released its earnings results on May 06, 2025. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.124 by -$0.086.
Is Neuronetics overvalued?
According to Wall Street analysts Neuronetics’s price is currently Undervalued.
Does Neuronetics pay dividends?
Neuronetics does not currently pay dividends.
What is Neuronetics’s EPS estimate?
Neuronetics’s EPS estimate is -0.08.
How many shares outstanding does Neuronetics have?
Neuronetics has 65,820,340 shares outstanding.
What happened to Neuronetics’s price movement after its last earnings report?
Neuronetics reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.124. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Neuronetics?
Currently, no hedge funds are holding shares in STIM
Neuronetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (108.88% Upside)
$8.00 (108.88% Upside)
Blogger Sentiment
Bullish
STIM Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 521.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $863.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.52%
12-Months-Change
Fundamentals
Return on Equity
-152.14%
Trailing 12-Months
Asset Growth
36.78%
Trailing 12-Months
Company Description
Neuronetics
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
STIM Company Deck
STIM Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted robust revenue growth driven by the Greenbrook acquisition and successful execution of strategic initiatives such as the BMP program and SPRAVATO rollout. However, challenges were noted in terms of decreased gross margin, increased operating expenses, and a widened net loss. Despite these challenges, the company remains on track to achieve cash flow positivity by the third quarter.Read More>STIM Stock 12 Month Forecast
Average Price Target
$8.00
▲(108.88%Upside)